EA202190359A1 - Способы лечения нейродегенеративных расстройств - Google Patents
Способы лечения нейродегенеративных расстройствInfo
- Publication number
- EA202190359A1 EA202190359A1 EA202190359A EA202190359A EA202190359A1 EA 202190359 A1 EA202190359 A1 EA 202190359A1 EA 202190359 A EA202190359 A EA 202190359A EA 202190359 A EA202190359 A EA 202190359A EA 202190359 A1 EA202190359 A1 EA 202190359A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- methods
- neurodegenerative disorders
- amyloid
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
В изобретении предложено применение соединения формулы (I)или его фармацевтически приемлемой соли для лечения заболевания, характеризующегося амилоидом и амилоидоподобными агрегатами, например болезни Альцгеймера.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713056P | 2018-08-01 | 2018-08-01 | |
| PCT/US2019/044114 WO2020028348A1 (en) | 2018-08-01 | 2019-07-30 | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190359A1 true EA202190359A1 (ru) | 2021-09-27 |
Family
ID=67587959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190359A EA202190359A1 (ru) | 2018-08-01 | 2019-07-30 | Способы лечения нейродегенеративных расстройств |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220087967A1 (ru) |
| EP (2) | EP4296670A3 (ru) |
| JP (1) | JP7466520B2 (ru) |
| KR (1) | KR20210039416A (ru) |
| CN (1) | CN112867487A (ru) |
| AU (1) | AU2019314323A1 (ru) |
| BR (1) | BR112021001718A2 (ru) |
| CA (1) | CA3108182A1 (ru) |
| DK (1) | DK3829568T3 (ru) |
| EA (1) | EA202190359A1 (ru) |
| ES (1) | ES2969887T3 (ru) |
| FI (1) | FI3829568T3 (ru) |
| HR (1) | HRP20231576T1 (ru) |
| HU (1) | HUE064501T2 (ru) |
| IL (1) | IL280441A (ru) |
| LT (1) | LT3829568T (ru) |
| MX (1) | MX2021001273A (ru) |
| PL (1) | PL3829568T3 (ru) |
| PT (1) | PT3829568T (ru) |
| RS (1) | RS65022B1 (ru) |
| SG (1) | SG11202100761PA (ru) |
| SI (1) | SI3829568T1 (ru) |
| WO (1) | WO2020028348A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114315655A (zh) * | 2021-12-18 | 2022-04-12 | 青岛科技大学 | 一种吸电子基团的不饱和烷烃的磺化方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| CN100571701C (zh) * | 2002-12-24 | 2009-12-23 | 贝卢斯健康(国际）有限公司 | 治疗β淀粉样蛋白相关疾病的治疗性制品 |
| ES2960625T3 (es) * | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| US11191742B2 (en) * | 2015-09-10 | 2021-12-07 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2019
- 2019-07-30 HR HRP20231576TT patent/HRP20231576T1/hr unknown
- 2019-07-30 BR BR112021001718-6A patent/BR112021001718A2/pt unknown
- 2019-07-30 CA CA3108182A patent/CA3108182A1/en active Pending
- 2019-07-30 SI SI201930675T patent/SI3829568T1/sl unknown
- 2019-07-30 EP EP23188362.0A patent/EP4296670A3/en active Pending
- 2019-07-30 FI FIEP19752609.8T patent/FI3829568T3/fi active
- 2019-07-30 KR KR1020217005804A patent/KR20210039416A/ko unknown
- 2019-07-30 CN CN201980064442.3A patent/CN112867487A/zh active Pending
- 2019-07-30 LT LTEPPCT/US2019/044114T patent/LT3829568T/lt unknown
- 2019-07-30 ES ES19752609T patent/ES2969887T3/es active Active
- 2019-07-30 EP EP19752609.8A patent/EP3829568B1/en active Active
- 2019-07-30 WO PCT/US2019/044114 patent/WO2020028348A1/en active Application Filing
- 2019-07-30 SG SG11202100761PA patent/SG11202100761PA/en unknown
- 2019-07-30 US US17/264,478 patent/US20220087967A1/en active Pending
- 2019-07-30 RS RS20231168A patent/RS65022B1/sr unknown
- 2019-07-30 MX MX2021001273A patent/MX2021001273A/es unknown
- 2019-07-30 EA EA202190359A patent/EA202190359A1/ru unknown
- 2019-07-30 JP JP2021505732A patent/JP7466520B2/ja active Active
- 2019-07-30 PT PT197526098T patent/PT3829568T/pt unknown
- 2019-07-30 PL PL19752609.8T patent/PL3829568T3/pl unknown
- 2019-07-30 DK DK19752609.8T patent/DK3829568T3/da active
- 2019-07-30 HU HUE19752609A patent/HUE064501T2/hu unknown
- 2019-07-30 AU AU2019314323A patent/AU2019314323A1/en active Pending
-
2021
- 2021-01-27 IL IL280441A patent/IL280441A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019314323A1 (en) | 2021-03-18 |
| JP2021534086A (ja) | 2021-12-09 |
| PT3829568T (pt) | 2023-12-14 |
| CN112867487A (zh) | 2021-05-28 |
| SI3829568T1 (sl) | 2024-02-29 |
| BR112021001718A2 (pt) | 2021-04-27 |
| FI3829568T3 (fi) | 2023-12-04 |
| PL3829568T3 (pl) | 2024-03-25 |
| WO2020028348A1 (en) | 2020-02-06 |
| HUE064501T2 (hu) | 2024-03-28 |
| EP3829568A1 (en) | 2021-06-09 |
| DK3829568T3 (en) | 2023-12-18 |
| KR20210039416A (ko) | 2021-04-09 |
| EP4296670A3 (en) | 2024-03-13 |
| EP4296670A2 (en) | 2023-12-27 |
| MX2021001273A (es) | 2021-07-15 |
| CA3108182A1 (en) | 2020-02-06 |
| ES2969887T3 (es) | 2024-05-23 |
| IL280441A (en) | 2021-03-01 |
| HRP20231576T1 (hr) | 2024-03-15 |
| LT3829568T (lt) | 2023-12-27 |
| SG11202100761PA (en) | 2021-02-25 |
| RS65022B1 (sr) | 2024-01-31 |
| JP7466520B2 (ja) | 2024-04-12 |
| EP3829568B1 (en) | 2023-09-06 |
| US20220087967A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
| DOP2020000037A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| NZ712207A (en) | Tetrahydropyrrolothiazine compounds | |
| EA202090987A1 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| TN2019000033A1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| EA202190359A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| TN2017000448A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| EA202090194A1 (ru) | Композиции статинов и способы их применения при лечении синуклеинопатий | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| PH12021550213A1 (en) | Methods for treating neurodegenerative disorders | |
| PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| EA202192382A1 (ru) | Соединения, нацеленные на prmt5 | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |